VIRX News and Press, Viracta Therapeutics Inc. From 01/08/23

Partial response (PR) observed in third dose level of the Phase 1b dose escalation study of Nana-val in EBV + recurrent/metastatic (R/M) nasopharyngeal carcinoma (NPC); enrollment into forth dose level is ongoing Anticipates clinical program updates from pivotal NAVAL-1 st...

SAN DIEGO, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today reported preliminary dose-ranging data from the first two dose levels ...

Viracta Therapeutics press release ( NASDAQ: VIRX ): Q3 GAAP EPS of -$0.47. Cash, cash equivalents and short-term investments totaled approximately $77.1 million as of September 30, 2022, Research and development expenses were approximately $7.1 million and $19.6 milli...

Pivotal NAVAL-1 trial of Nana-val in Epstein-Barr virus-positive (EBV + ) lymphoma open for enrollment at more than 50 sites worldwide; update on the first indication that may advance from Stage 1 to Stage 2 now anticipated in the first half of 2023 Completed initial...

Viracta Therapeutics ( NASDAQ: VIRX ) on Monday appointed Mark Rothera as its president and CEO, succeeding Ivor Royston. Royston will continue to serve as a member of VIRX's board, the company said in a statement . VIRX said Rothera had more than 30 years of ...

Viracta Therapeutics Announces Chief Executive Officer Leadership Succession to Drive the Next Phase of the Company's Strategic Development and Growth PR Newswire Viracta Therapeutics' Board of Directors appoints Mark Rothera as President and Chief Executive Office...

Viracta Therapeutics ( NASDAQ: VIRX ) on Wednesday said the European Commission had granted an orphan drug designation to its all-oral combination product candidate Nana-val for the treatment of peripheral T-cell lymphoma. The company said this was its first such ...

Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission for Nana-val for the Treatment of Peripheral T-cell Lymphoma PR Newswire First orphan drug designation granted for Nana-val by the European Commission; fifth globally SA...

Viracta Therapeutics Chief Scientific Officer, Dr. Ayman Elguindy, Elected to the Governing Board of the International Association for Research on Epstein-Barr Virus and Associated Diseases PR Newswire SAN DIEGO , Aug. 16, 2022 /PRNewswire/ -- Viracta ...

Viracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors PR Newswire SAN DIEGO , Aug. 11, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. ( Nasdaq : VIRX ), a precision oncology company targeting virus-associated malignanci...